# Elixir Medical Corporation

> Elixir Medical Corporation is a privately held Milpitas, California medical device company building implantable technologies to treat coronary and peripheral artery disease. Its flagship DynamX Coronary Bioadaptor is a metal implant with a resorbable polymer coating that dissolves over roughly six months, 'uncaging' the artery so the vessel can pulse and move naturally rather than remaining permanently rigid like a conventional stent. Founded in 2005 by Motasim Sirhan, Elixir has produced a lineage of coronary devices - the DESolve bioresorbable scaffold, the DESyne family of drug-eluting stents, the LithiX intravascular lithotripsy system, and the DynamX bioadaptor - and has reported two consecutive randomized trials showing reduced long-term cardiac event rates versus current drug-eluting stents.

- **Founded:** 2005
- **Headquarters:** Milpitas, California, United States
- **Founders:** Motasim Sirhan (Founder & CEO)
- **Team size:** ~96 employees
- **Products:** DynamX Coronary Bioadaptor System, DESyne X2 Novolimus-Eluting Coronary Stent System, LithiX Hertz Contact (HC) Intravascular Lithotripsy System, DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System
- **Notable:** DynamX bioadaptor granted FDA Breakthrough Device Designation (June 2024) for symptomatic ischemic heart disease., INFINITY-SWEDEHEART randomized trial (2,400 patients) met its primary endpoint (ESC Congress 2024)., Reported ~48% reduction in Target Lesion Failure vs. a contemporary drug-eluting stent from six months through two years.

## Products & services

- **DynamX Coronary Bioadaptor System** — A sirolimus-eluting metal implant with a bioresorbable polymer coating that provides stent-like radial strength, then 'uncages' after roughly six months as the polymer resorbs - restoring vessel pulsatility, compliance and adaptive blood flow, and associated with plaque stabilization and regression.
- **DESyne X2 Novolimus-Eluting Coronary Stent System** — A thin-strut durable drug-eluting stent in Elixir's DESyne family of coronary stents.
- **LithiX Hertz Contact (HC) Intravascular Lithotripsy System** — A device to fracture coronary calcium and prepare calcified lesions ahead of stenting or bioadaptor placement.
- **DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System** — A poly-L-lactide bioresorbable scaffold eluting novolimus that supports the vessel and then fully resorbs; earlier DESolve and DESolve 100 (100-micron struts) received CE Mark.

## Achievements

- DynamX bioadaptor granted FDA Breakthrough Device Designation (June 2024) for symptomatic ischemic heart disease.
- INFINITY-SWEDEHEART randomized trial (2,400 patients) met its primary endpoint (ESC Congress 2024).
- Reported ~48% reduction in Target Lesion Failure vs. a contemporary drug-eluting stent from six months through two years.
- First interventional technology to report significant long-term event reduction in two consecutive randomized controlled trials.
- Received European CE Mark for the DESolve 100, described as the world's first bioresorbable scaffold with 100-micron struts.
- Sustained lower event rates vs. drug-eluting stent demonstrated through three years (EuroPCR 2025).

## Latest updates

- **2026-05** — At EuroPCR 2026, Elixir reported DynamX bioadaptor demonstrating significantly lower event rates than a drug-eluting stent.
- **2025-10** — At TCT 2025, late-breaking INFINITY-SWEDEHEART data showed nearly a 50% reduction in coronary event rates vs. the current PCI standard of care through two years.
- **2025-05** — At EuroPCR 2025, late-breaking data showed sustained significantly lower event rates for DynamX vs. drug-eluting stent through three years.
- **2024-09** — INFINITY-SWEDEHEART trial met its primary endpoint at ESC Congress 2024.
- **2024-06** — DynamX Sirolimus-Eluting Coronary Bioadaptor System granted FDA Breakthrough Device Designation.

## Links

- Website: https://elixirmedical.com
- LinkedIn: http://www.linkedin.com/company/elixir-medical-corporation
- Twitter/X: https://twitter.com/elixirmed
- Facebook: https://facebook.com/ElixirMedicalSEA/

---

Profile page: https://yespress.io/elixir-medical-corporation
Published by YesPress — https://yespress.io
Last updated: 2026-07-12